Timing of treatment initiation in Parkinson's disease: A need for reappraisal?

被引：147

作者：

Schapira, AHV

Obeso, J

机构：

[1] Univ London, Dept Clin Neurosci, Royal Free & Univ Coll, Sch Med, London NW3 2PF, England

[2] UCL, Inst Neurol, London WC1E 6BT, England

[3] Univ Navarra, Div Neurosci, Dept Neurol & Neurosurg, E-31080 Pamplona, Spain

[4] CIMA, Pamplona, Spain

来源：

ANNALS OF NEUROLOGY | 2006年 / 59卷 / 03期

关键词：

D O I：

10.1002/ana.20789

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

引用

页码：559 / 562

页数：4

共 31 条

[1] Slowing Parkinson's disease progression - Recent dopamine agonist trials [J].

Ahlskog, JE .

NEUROLOGY, 2003, 60 (03) :381-389

[2] Involvement of the subthalamic nucleus in glutamatergic compensatory mechanisms [J].

Bézard, E ;

Boraud, T ;

Bioulac, B ;

Gross, CE .

EUROPEAN JOURNAL OF NEUROSCIENCE, 1999, 11 (06) :2167-2170

[3] Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease [J].

Bezard, E ;

Dovero, S ;

Prunier, C ;

Ravenscroft, P ;

Chalon, S ;

Guilloteau, D ;

Crossman, AR ;

Bioulac, B ;

Brotchie, JM ;

Gross, CE .

JOURNAL OF NEUROSCIENCE, 2001, 21 (17) :6853-6861

[4]

CALABRESI P, 1993, BRAIN, V116, P433

[5]

Fahn S, 2004, NEW ENGL J MED, V351, P2498

[6] AGING AND PARKINSONS-DISEASE - SUBSTANTIA-NIGRA REGIONAL SELECTIVITY [J].

FEARNLEY, JM ;

LEES, AJ .

BRAIN, 1991, 114 :2283-2301

[7] Sydney multicenter study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years [J].

Hely, MA ;

Morris, JGL ;

Reid, WGJ ;

Trafficante, R .

MOVEMENT DISORDERS, 2005, 20 (02) :190-199

[8] Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity [J].

Hilker, R ;

Schweitzer, K ;

Coburger, S ;

Ghaemi, M ;

Weisenbach, S ;

Jacobs, AH ;

Rudolf, J ;

Herholz, K ;

Heiss, WD .

ARCHIVES OF NEUROLOGY, 2005, 62 (03) :378-382

[9] Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson's disease [J].

Jenner, P .

NEUROLOGY, 2004, 63 (07) :S13-S22

[10] Oxidative stress in Parkinson's disease [J].

Jenner, P .

ANNALS OF NEUROLOGY, 2003, 53 :S26-S36

← 1 2 3 4 →